ClinicalTrialsFinder

Subjects Considered Likely to Respond to CB-03-10 Clinical Trials in New Haven, Connecticut

1 recruitingNew Haven, Connecticut

Showing 1–1 of 1 trials

Recruiting
Early Phase 1

Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

Advanced Refractory Solid TumorsSubjects Considered Likely to Respond to CB-03-10
Cosmo Technologies Ltd90 enrolled6 locationsNCT03863145